Cargando…

P1075: EVALUATION OF CYTOKIN GENE POLYMOPHISMS AND GENE EXPRESSIONS IN PATIENTS WITH HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales:	Haydaroglu Sahin, H., Demirbas, D. D., Akkurd, D. M., Okan, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430413/ http://dx.doi.org/10.1097/01.HS9.0000847168.28056.7c

Ejemplares similares

PB2151: EVALUATION OF BONE MINERAL DENSITY IN LYMPHOMA PATIENTS WITH USING PET/CT AND THE ROLE OF BCL-2
por: Okan, V., et al.
Publicado: (2022)

PB1951: INVESTIGATION OF THE RELATIONSHIP BETWEEN CD56 AND CD117 EXPRESSIONS AND CLINICAL AND LABORATORY FINDINGS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS
por: Akkurd, D. M., et al.
Publicado: (2022)

Angiotensin-Converting Enzyme Gene Polymophism in Adult Primary Focal Segmental Glomerulosclerosis
por: Mohd, Rozita, et al.
Publicado: (2014)

Neurolymphomatosis in non-Hodgkin lymphoma with cranial multineuritis: A case report
por: Haydaroglu Sahin, Handan, et al.
Publicado: (2018)

P1085: EVALUATION OF GONADAL FUNCTION IN YOUNG WOMEN DIAGNOSED WITH HODGKIN AND NON-HODGKIN LYMPHOMA
por: Georgopoulou, A. N., et al.
Publicado: (2022)

P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS
por: Cellini, Alessandro, et al.
Publicado: (2023)

P1531: TIXAGEVIMAB-CILGAVIMAB THERAPY IN THE PREVENTION OF SARS-COV2 INFECTION IN NON-HODGKIN-B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE
por: Pezzullo, Luca, et al.
Publicado: (2023)

Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts?
por: Haydaroglu Sahin, Handan
Publicado: (2019)

P1077: HODGKIN LYMPHOMA IN PATIENTS WITH HIV: NATIONAL RETROSPECTIVE MULTICENTER STUDY
por: Chekalov, A., et al.
Publicado: (2022)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

P1074: PRIMARY REFRACTORY HODGKIN’S LYMPHOMA: A MOROCCAN MONOCENTRIC RETROSPECTIVE STUDY
por: Ababou, M., et al.
Publicado: (2022)

P1072: SIGNIFICANT PREDICTORS OF DECREASED BONE MINERAL DENSITY IN PATIENTS WITH HODGKIN’S LYMPHOMA
por: Voytko, Mariya, et al.
Publicado: (2023)

AB116. Role of the novel herbal formulation (WSY-1075) in a refractory detrusor overactivity due to bladder outlet obstruction
por: Bae, Woong Jin, et al.
Publicado: (2016)

1075. Absolute Lymphocyte Count as a Predictor of Cytomegalovirus (CMV) Infection and Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Reekie, Joanne, et al.
Publicado: (2020)

P1288: ALTERED AMINO ACID HOMEOSTASIS CAN ELICIT AN ADAPTIVE RESPONSE VIA UPREGULATION OF UFMYLATION IN HODGKIN LYMPHOMA
por: Romano, A., et al.
Publicado: (2022)

P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
por: Mulder, T. A., et al.
Publicado: (2022)

P1241: A NOVEL CEREBLON-BINDING MOLECULAR GLUE, SP-3164, SHOWS PRECLINICAL ACTIVITY IN NON-HODGKIN LYMPHOMAS
por: Santiesteban, Daniela, et al.
Publicado: (2023)

AB099. The anti-inflammatory and anti-microbial effects of the novel herbal formulation (WSY-1075) on chronic bacterial prostatitis rat model
por: Bae, Woong Jin, et al.
Publicado: (2016)

P1093: A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED-STAGE HODGKIN LYMPHOMA.
por: Rask Kragh Jørgensen, R., et al.
Publicado: (2022)

P1274: EARLY DETECTION OF NON-HODGKIN LYMPHOMA IN PREDISPOSED PATIENT GROUPS THROUGH IMMUNOGENETIC SEQUENCING
por: Kolijn, P. M., et al.
Publicado: (2022)

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2023)

Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma
por: Nagel, Stefan, et al.
Publicado: (2015)

Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma
por: Nagel, Stefan, et al.
Publicado: (2018)

P1091: FEASIBILITY OF ASCT AFTER ANTI-PD-1 THERAPY FOR R/R CLASSICAL HODGKIN LYMPHOMA
por: Mochkin, N., et al.
Publicado: (2022)

P1092: NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA (NLPHL): HISTOLOGYCAL AND CLINICAL REVIEW IN A SINGLE CENTRE.
por: Rámila, E., et al.
Publicado: (2022)

P1430: GUT MICROBIOTA DIVERSITY AND BUTYRATE PRODUCERS IMPACTS ON NON-HODGKIN LYMPHOMA PATIENTS RESPONSE TO CD19 CAR-T THERAPY
por: Garcia-Vicente, R., et al.
Publicado: (2022)

CYP1A1, mEH, and GSTM1 Polymophisms and Risk of Oral and Pharyngeal Cancer: A Spanish Case-Control Study
por: Varela-Lema, L., et al.
Publicado: (2008)

1075. In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized Fluoroquinolone Resistant Subsets
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Cytokine gene expression profiling identifies distinct patterns in severe sepsis
por: Sarveswaran, J, et al.
Publicado: (2012)

P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN’S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP).
por: Gaudio, F., et al.
Publicado: (2022)

Novel prognostic nomograms in cervical cancer based on analysis of 1075 patients
por: Rao, Qunxian, et al.
Publicado: (2022)

P1589: AGENTS CONTRIBUTING TO SECONDARY IMMUNODEFICIENCY DEVELOPMENT IN PATIENTS WITH MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW
por: Jolles, S., et al.
Publicado: (2022)

P1217: TARGETING HSP110 IN COMBINATION WITH SELINEXOR IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA AND IN CLASSICAL HODGKIN LYMPHOMA INHIBITS STAT6 ACTIVATION AND IMPAIRS LYMPHOMA CELL GROWTH
por: Durand, Manon, et al.
Publicado: (2023)

P1076: A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN’S LYMPHOMA IN THE PET-GUIDED ERA
por: Cellini, A., et al.
Publicado: (2022)

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
por: Cheah, C. Y., et al.
Publicado: (2022)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
por: Prochazka, Vit, et al.
Publicado: (2022)

Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma
por: Lennerz, Jochen K., et al.
Publicado: (2015)

Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas
por: Nielsen, Julie S, et al.
Publicado: (2015)

P1746: LONG-TERM NON-HODGKIN LYMPHOMA SURVIVORS IN CÔTE D’OR: HEALTH-RELATED QUALITY OF LIFE AND LIVING CONDITIONS.
por: Wasse, S., et al.
Publicado: (2022)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1j2r9mnunc91o6m41i6i9clq87